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Abstract
Introduction: The purpose of the study was to comprehensively evaluate physiologic changes associated with
development of high altitude pulmonary edema (HAPE). We tested whether changes in pulmonary function and breathing
pattern would herald clinically overt HAPE at an early stage.
Methods: In 18 mountaineers, spirometry, diffusing capacity, nitrogen washout, nocturnal ventilation and pulse oximetry
were recorded at 490 m and during 3 days after rapid ascent to 4559 m. Findings were compared among subjects
developing HAPE and those remaining well (controls).
Results: In 8 subjects subsequently developing radiographically documented HAPE at 4559 m, median FVC declined to 82%
of low altitude baseline while closing volume increased to 164% of baseline (P,0.05, both instances). In 10 controls, FVC
decreased slightly (to 93% baseline, P,0.05) but significantly less than in subjects with HAPE and closing volume remained
unchanged. Sniff nasal pressure was reduced in both subjects with and without subsequent HAPE. During nights at 4559 m,
mean nocturnal oxygen saturation dropped to lower values while minute ventilation, the number of periodic breathing
cycles and heart rate were higher (60%; 8.6 L/min; 97 cycles/h; 94 beats/min, respectively) in subjects subsequently
developing HAPE than in controls (73%; 5.1 L/min; 48 cycles/h; 79 beats/min; P,0.05 vs. HAPE, all instances).
Conclusion: The results comprehensively represent the pattern of physiologic alterations that precede overt HAPE. The
changes in lung function are consistent with reduced lung compliance and impaired gas exchange. Pronounced nocturnal
hypoxemia, ventilatory control instability and sympathetic stimulation are further signs of subsequent overt HAPE.
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Introduction
High altitude pulmonary edema (HAPE) is a potentially life-
threatening condition that occurs after rapid ascent to high
altitude. Mountaineers with a previous history of HAPE are at
particular risk. The diagnosis at high altitude is based on the
presence of dyspnoea, tachypnea, cough, pulmonary crackles,
and cyanosis. A chest radiograph demonstrates pulmonary
infiltrates but this is rarely available in the mountains. Since
HAPE is preventable and treatable, it would be desirable, if
early diagnosis was feasible by detecting physiologic changes
that precede overt HAPE. Cremona and colleagues reported on
the potential role of closing volume as a sensitive marker of
early subclinical HAPE [1]. However, in a previous study we
observed increases in closing volume even in some subjects not
developing HAPE after rapid ascent to the Capanna Regina
Margherita (4559 m) [2]. In contrast, Dehnert and colleagues
found no changes in closing volume or other pulmonary
function tests in subjects without a history of HAPE ascending
to Capanna Regina Margherita [3]. The purpose of the current
study was therefore to further investigate physiologic character-
istics differentiating subjects developing HAPE from those
remaining free of HAPE. While previous studies had separately
focused on various specific aspects [1,3,4] the purpose of the
current study was to perform a comprehensive evaluation
including pulmonary function, blood gases and nocturnal
polygraphic recordings in subjects developing HAPE in com-
parison to healthy controls at 4559 m in order to better
understand the time course and pattern of physiologic
alterations associated with HAPE. We evaluated whether
changes in pulmonary function and breathing pattern would
herald clinically overt HAPE at an early stage.
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Methods
Subjects
The study population consisted in 8 HAPE susceptible subjects
with a history of previous radiologically documented HAPE and
10 healthy controls without a history of HAPE (controls). Data
were collected as part of studies on prevention of HAPE by
dexamethasone and tadalafil [5] and on platelet function at
altitude [6], respectively. The time period and setting of the study
was the same for both groups. Seven of the HAPE susceptible
subjects had received placebo and one subject had received the
phosphodiesterase inhibitor tadalafil (10 mg twice daily beginning
on the day before ascent to altitude) as part of the trial. All other
HAPE susceptible subjects included in the prevention trial did not
develop HAPE, hence were not included in the present in-
vestigation. The subject’s characteristics are summarized in
Table 1.
Study Protocol
Low altitude baseline evaluation including clinical examination,
pulmonary function and nocturnal polygraphic monitoring were
carried out in Zurich (490 m) within 1 month before ascent to
altitude. Control subjects had all examinations with exception of
polygraphic monitoring at 490 m. Study participants travelled
from Alagna, Italy, 1130 m, to 3200 m by cable car and
subsequently hiked 2 hours to the Gnifetti hut (3647 m), where
they spent one night. In the following morning, subjects hiked to
Capanna Margherita, 4559 m, within 4–5 h and stayed there for 3
days. Daytime examinations were performed 4–6 h after arrival at
4559 m (day 1) and in the mornings of day 2 and 3, nocturnal
polygraphic monitoring was performed during all nights at
4559 m. The diagnosis of HAPE was suspected on clinical
grounds (excessive dyspnea, tachypnea, dry cough, cyanosis) and
confirmed by chest radiography. Subjects with radiographically
confirmed HAPE were treated with oxygen and nifedipine and no
further tests were performed in them. The last data obtained
before the diagnosis of HAPE is reported as endpoint for the
current study.
Measurements
Clinical assessment. A medical history was obtained and
a physical examination performed. Acute mountain sickness
(AMS) was assessed by the Lake Louise consensus scoring system
[7]. A score .4 was considered as representing clinically relevant
AMS.
Lung function and blood gas analysis. Oxygen saturation
was measured by pulse oximetry in the sitting position after
15 min of quiet rest. Spirometry and single breath diffusing
capacity were performed according to standard techniques (Vmax
system, SensorMedics, Fullerton CA, USA) [8,9]. For diffusing
capacity (DLCO), the unadjusted (standard) values and the values
adjusted for high altitude (DLCOadj) are reported:
DLCOadj =DLCO*(1+0.0031 * [(PB - 47) * 0.21–149]) [8,9].
Calibrations of the flow meter and gas analyzers were performed
several times a day. Reference values were those of the European
Community for Steel and Coal [10]. The nitrogen washout test
was performed in the same way as in our previous study and
described in detail [2]. Maximal inspiratory and sniff nasal
pressures were measured according to standard techniques
(MicroRPM, Micro Medical, Kent, UK) [11]. Arterial blood
gases were measured (ABL 5 Radiometer, Copenhagen, Denmark)
and partial pressure of alveolar oxygen was calculated [12].
Nocturnal polygraphic recordings. Nocturnal polygraphic
monitoring was performed and analyzed as previously described
[13]. Briefly, a portable device incorporating calibrated respiratory
inductance plethysmography, pulse oximetry, ECG and a body
position sensor were employed (LifeShirt System, VivoMetrics,
Ventura, CA, USA). Inductance sensors were embedded into
a snugly fitting shirt. The respiratory inductance plethysmograph
was calibrated by the Qualitative Diagnostic Calibration pro-
cedure (QDC) during natural breathing [14] followed by fixed
volume calibration during rebreathing into a bag of 0.8L for 5 to
10 breaths with the nose clipped. Calibration was verified in the
morning after sleep studies and found to be within 20% of the
evening value in all instances. Apneas/hypopneas and periodic
breathing were scored as previously described. The apnea/
hypopnea index was defined as number of apneas and hypopneas
per hour. The fraction of the night spent in periodic breathing was
measured. The oxygen desaturation index was defined as number
of .3% dips per hour.
Chest radiography. A chest radiograph was obtained at
490 m and on day 1 and 3 at high altitude or if HAPE was
suspected. Chest radiographs were separately scored according to
the work by Vock et al. at the end of the study by investigators
blinded to the clinical findings and chronological sequence of the
examinations [15].
Ethics. The ethics committee of the university hospital of
Zurich approved the protocol and all subjects gave written
informed consent.
Data analysis and statistics. Results are shown as means
(SD) or medians (quartiles), as appropriate. Measurements at
different altitudes and between groups were compared by analysis
of variance for repeated measures with Newman-Keuls post-hoc
test if appropriate. A probability of P,0.05 was considered
significant.
Results
Eight subjects developed HAPE, 4 on day 2 and 4 on day 3. As
per definition, all 8 subjects developing HAPE had radiological
and physical evidence of HAPE. Conversely, none of the control
subjects had symptoms or clinical signs of HAPE. AMS (Lake
Louise score .4) occurred in 7 of 8 subjects developing HAPE
(mean score 7.062.8) and in 5 of the 10 control subjects (mean
score 4.562.1, P= 0.04). The tables present mean data (6SD)
from subjects developing HAPE and controls for measurements at
low altitude (490 m), after arrival at 4559 m and at the time of the
last measurement before overt HAPE. The median time lag
(quartile range) between the last pulmonary function test and
diagnosis of HAPE was 8.5 (4.5–12.0) hours. None of the control
subjects developed HAPE. Therefore, their last evaluation was on
the third day at 4559 m.
Table 1. Subjects characteristics.
Controls HAPE-group
Number of subjects (females) 10 (1) 8 (1)
Age (years) 32 (3.5) 40 (9.4)*
Height (m) 1.78 (0.06) 1.76 (0.07)
Weight (kg) 75 (9.0) 74 (9.2)
BMI (kg/m2) 23.6 (3.0) 23.8 (2.3)
Values are presented as mean (SD), *P,0.05 vs. controls.
doi:10.1371/journal.pone.0041188.t001
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Figure 1. Changes in lung function in subjects developing HAPE and in healthy controls. FVC (upper panel), closing volume above RV
(middle panel) and DLCO adjusted for PIO2 (lower panel), all expressed in percent of the value at 490 m. HAPE = subjects subsequently developing
HAPE, controls = subjects not developing HAPE; first and last day at 4559 m = values measured on the day of arrival and either on the last day
before clinically overt HAPE occurred, or on day 3 in controls. *P,0.05 vs. 490 m. **P,0.05 vs. controls.
doi:10.1371/journal.pone.0041188.g001
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Lung Function
Results of pulmonary function tests are summarized in table 2
and illustrated in figure 1. On the day of arrival at 4559 m,
FVC (% pred.) had fallen significantly by a mean of 4%
compared to low altitude baseline in the control group and by
9% in the subjects developing HAPE. There was a further
decrease by a mean of 3% in controls and 12% in subjects
developing HAPE at their last measurement at 4559 m. FEV1
(% pred.) did not change at high altitude in the control group,
however in subjects developing HAPE it was decreased on the
last assessment before HAPE occurred. We observed a significant
uniform increase in closing volume in the HAPE group at
4559 m, which was in contrast to corresponding values in the
control group which revealed variable changes and remained
statistically unchanged at altitude compared to 490 m. More-
over the slope of phase III of the nitrogen washout test was
increased in the final measurement in subjects developing
HAPE. Sniff nasal inspiratory pressure (SNIP) decreased in
controls already on the day of arrival at 4559 m while subjects
developing HAPE revealed a significant decrease in sniff nasal
pressure on their last assessment.
Pulse oximetry revealed lower values in subjects developing
HAPE already on the day of arrival at 4559 m and their oxygen
saturation remained significantly lower until the end of the study.
Carbon monoxide diffusing capacity increased at altitude due to
the reduced barometric pressure (and PIO2). Adjustment of
DLCO for the lower PIO2 at altitude revealed no changes in
controls but a reduction in subjects developing HAPE in the final
measurement.
Nocturnal Polygraphic Recordings
The results of nocturnal polygraphic recordings are summarized
in table 3. In agreement with the daytime measurements, mean
oxygen saturation was significantly lower in subjects developing
HAPE than in controls already during the first night at 4559 m
(6268% vs. 7363%, P,0.01). This was in spite of the fact that
subjects developing HAPE were breathing faster and at a higher
tidal volume than controls and therefore achieved higher minute
ventilation. Both groups had pronounced periodic breathing at
4559 m and the highest apnea/hypopnea index was observed in
the group developing HAPE.
Table 2. Pulmonary function and arterial blood gas analysis.
Controls (n =10) HAPE-group (n =8)
490 m, baseline 4559 m, day 1 4559 m, day 3 490 m, baseline 4559 m, day 1
4559 m, last
evaluation
FVC, L 5.6460.56 5.4160.48* 5.2660.53* 5.0761.32 4.6561.11* 4.0760.93*
FVC, % predicted 113613 109613* 106613* 108617 99616* 87615*#
FEV1, L 4.3560.43 4.2860.30 4.1260.46 3.8561.30 3.6060.98* 3.2360.89*
FEV1, % predicted 104612 10269 9861 98623 93619 83618*
FEV1/FVC 7766 7967 7968 7569 7766 7967*
PEF, L/sec 9.3861.10 10.4461.29* 10.0061.13 7.8162.48 9.0563.15* 8.6162.10
PEF, % predicted 99612 110615* 105613 85620 98626* 96623
N2 washout, slope of phase III, %N2/L 0.8360.26 0.9160.32 0.9360.33 0.8360.43 1.0960.62 1.2160.66*
N2 washout, CV, L above RV 0.4060.10 0.4360.08 0.4160.07 0.3360.06 0.5360.14*
" 0.5160.05*"
RV, L 1.5260.31 1.6360.42 1.6060.37 1.6360.45 1.5960.37 1.5960.37
RV, % predicted 85.6613.2 91.5619.2 89.9617.1 84.9622.8 83.1618.7 82.8617.1
TLC, L 6.7461.17 6.7960.73 6.7960.82 6.4161.43 6.0961.35 5.4861.06*
TLC, % predicted 94.9612.2 97.069.9 97.069.4 92.6613.4 88.5611.7 80.3610.0*
DLCO, ml/mmHg/min 37.166.7 46.466.3* 44.667.3* 34.167.2 45.069.0* 37.266.2
DLCO, % predicted 107616 134617* 129620* 104611 138611* 115610
DLCO, % pred. PIO2 adj. 103614 107614 102616 102611 10969 9168*
Pulse oximetry, SpO2% 9662 7965* 7768* 9661 68614*
" 68611*"
SNIP, cmH2O 99623 85620* 82627* 70613 78614 64615*
arterial pH 7.4160.02 7.4660.03 7.4660.02* 7.4160.01 7.4860.02 7.4960.01*"
PaCO2, mmHg 40.262.6 30.362.1 30.361.7* 40.162.3 29.062.6 28.862.0*
PaO2, mmHg 89.367.3 42.462.9* 46.162.9* 89.063.6 33.464.9*
" 30.163.6*"
AaPO2, mmHg 14.467.5 10.963.9 7.563.3* 14.7610.4 21.263.5 25.362.8*
"
SaO2 (%) 96.561.0 80.962.5* 83.262.9* 96.561.3 69.168.6*
" 63.067.4*"
Means 6SD. FVC, FEV1, PEF: forced expiratory vital capacity, expiratory volume in 1 sec and peak expiratory flow, respectively; CV: closing volume above residual
volume. TLC, RV: total lung capacity and residual volume measured by methane dilution; SNIP: sniff nasal inspiratory pressure; DLCO: carbon monoxide single-breath
diffusing capacity in absolute units, in % predicted and in % predicted after adjustment for reduced PIO2.
*P,0.05 vs. 490 m within group.
"P,0.05 vs. controls.
#P= 0.05 vs. controls.
doi:10.1371/journal.pone.0041188.t002
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Discussion
The current study provides a detailed account of respiratory
physiologic alterations preceding HAPE in susceptible subjects
ascending rapidly to 4559 m. The main changes comprised an
initial excessive drop in arterial oxygen saturation associated with
a reduction in static lung volumes including closing volume,
weakness of inspiratory muscles and an impaired diffusing
capacity. Increases in nocturnal breath rate and tidal volume
both contributed to augmented minute ventilation with frequent
oscillations and severe periodic oxygen desaturations. This pattern
is consistent with interstitial fluid accumulation preceding overt
HAPE impairing pulmonary diffusion by ventilation/perfusion
mismatch and reduction of pulmonary gas exchange surface
related to early closure of peripheral air spaces.
Previous studies on physiologic alterations associated with the
development of HAPE have mainly focused on hemodynamics,
biochemical changes and blood gases. Conversely, data on lung
function in subjects developing HAPE have been scant and
combined evaluations of pulmonary mechanical changes, gas
exchange and breathing patterns have not been reported. Our
study closes this gap by providing a comprehensive description of
the successive physiologic events.
Pulmonary Mechanics
Several studies described an early reduction in FVC in
mountaineers at altitudes of 3800–4559 m [2,16,17] and at
simulated altitude of 8848 m in a hypobaric chamber [18] and
our results corroborate these data. One single study of Dehnert
and colleagues is at variance with these otherwise consistent
findings across various altitudes and settings and there is no
obvious reason for the discrepancy [2,3].
Compared to the controls, the subjects developing HAPE had
a greater fall in FVC at 4559 m in the measurement that preceded
overt HAPE. Reductions in inspiratory muscle force have been
reported previously in hypobaric and normobaric hypoxia and
have been correlated with reductions in FVC [19]. The reasons for
the fall in FVC and TLC are most likely a combination of reduced
lung compliance due to interstitial fluid accumulation and
inspiratory muscle weakness as suggested by the reduced SNIP
preceding HAPE (table 2) [1,2]. A less favorable length-tension
relationship at lower lung volumes and other, yet unknown, factors
may additionally have impaired the force generating capacity of
inspiratory muscles.
An increase in closing volume associated with a reduction in
vital capacity has been suggested to reflect subclinical pulmonary
fluid accumulation in mountaineers [1]. The trend of alterations in
closing volume and FVC at 4559 m we observed in subjects
subsequently developing overt HAPE is consistent with these
assumptions (figure 1) and the fact that closing volume was
increased in each of them before symptomatic HAPE necessitated
treatment suggests sensitivity of this variable as a harbinger of
overt HAPE. In a previous study at 4559 m [1], closing volume
was increased in 34 of 37 mountaineers even without HAPE-
related symptoms but with physical diagnostic and/or radiological
evidence of (subclinical) HAPE. Premature closure of peripheral
air spaces due to a reduction in lung compliance by interstitial
fluid accumulation is the most likely explanation for the increased
closing volume since similar statistically significant increases
in closing volume did not occur in our controls (table 2) in whom
closing volume revealed no uniform trend with ascent to and
during stay at 4559 m. Differences in ascent rate and the
individual level of physical exertion during climbing might have
contributed to the variability of closing volumes in subjects without
subsequent HAPE since strenuous exercise promotes interstitial
pulmonary edema [20]. An increased closing volume is therefore
not a specific marker of HAPE. Since spirometry did not show any
evidence of airflow obstruction we do not assume that the increase
in closing volume can be explained by exercise or cold air-induced
bronchial constriction.
Pulmonary Gas Exchange
We observed that diffusing capacity (adjusted for the reduced
PIO2) remained unchanged in controls during the stay at
4559 m while subjects developing HAPE revealed a decrease in
DLCO before overt HAPE occurred. In subjects developing
HAPE, DLCO fell by more than 10% below low altitude
baseline (figure 1) suggesting impairment in the membrane
component of diffusion due to interstitial edema although
simultaneous changes in pulmonary capillary blood volume
Table 3. Nocturnal polygraphic monitoring.
Controls (n=10) HAPE-group (n =8)
4559 m, night 1 4559 m, night 2 490 m, baseline 4559 m, night 1 4559 m, last night
Recording time, min 472612 437665 446620 438689 3676138
Mean nocturnal SpO2, % 7363 7363 9561 6268*" 6068*"
Breath rate, 1/min 19.762.8 20.062.6 17.261.4 25.865.6*" 27.064.8*"
Tidal volume, L 0.2860.06 0.2560.06 0.2260.07 0.3060.13 0.3260.14
Ventilation, L/min 5.661.4 5.161.8 3.861.4 7.661.7*" 8.663.1*"
Mean inspiratory flow, L/sec 0.2160.05 0.1960.06 0.1660.05 0.2960.08*" 0.3360.01*"
%Time in Periodic Breathing 35630 30629 060 56620* 52620*
Apnea/hypopnea index, 1/h 58650 48644 262 101640* 97645*"
Oxygen desaturation index, dips .3%/h 37629 35632 161 66634* 59635*
Heart rate, 1/min 81610 79610 5967 90611* 9469*"
Means6SD; 490 m refers to the baseline examinations in Zurich performed in HAPE susceptibles exclusively; night 1 corresponds to the 1st measurement, last night to
the last measurement before overt HAPE occurred in the HAPE group and to the measurement in the 2nd night at 4559 m in controls respectively.
*P,0.05 vs. 490 m within group.
"P,0.05 vs. controls.
doi:10.1371/journal.pone.0041188.t003
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cannot be excluded [21]. Pulmonary gas exchange may also
have been impaired by uneven distribution of ventilation as
suggested by the increased slope of phase III in the nitrogen
washout test (table 2) with consecutive ventilation/perfusion
mismatch. Furthermore, the premature peripheral airway
closure commented above might have affected diffusion by
reducing the gas exchange surface of the lung. In line with the
reduced diffusing capacity, the arterial oxygen saturation was
excessively decreased during the day and the night in subjects
developing HAPE and the alveolar-arterial PO2 gradient was
increased (table 2).
Nocturnal Polygraphic Recordings
Consistent with an impaired pulmonary gas exchange and
reduced arterial oxygen saturation after arrival at 4559 m, subjects
subsequently developing HAPE also revealed a reduced nocturnal
oxygen saturation already during their first night at altitude.
Furthermore, they increased their ventilation, mean inspiratory
flow and heart rate consistent with an increased respiratory center
drive and a high sympathetic tone induced by progressive
hypoxemia and interstitial edema stimulating pulmonary stretch
receptors (table 3). Since high altitude periodic breathing is
triggered by hypoxia and increased ventilation, this finding might
explain the higher frequency of apneas/hypopneas in the last
recordings preceding HAPE in susceptible subjects. Whether
increases in pulmonary artery and pulmonary capillary pressure
may have contributed to periodic breathing through stimulation of
strain receptors similar to the findings in patients with pulmonary
hypertension of other etiology [22] or in patients with left heart
failure [23] remains open.
In conclusion, our data demonstrate that clinically overt HAPE
is preceded by a pattern of alterations in pulmonary mechanics
and gas exchange that are consistent with reduced compliance and
respiratory muscle strength, uneven distribution of ventilation and
gas exchange impairments that are caused by interstitial fluid
accumulation. Future studies might evaluate simple, portable
measurement techniques suitable for screening mountaineers in
the field for early evidence of a physiologic pattern indicating
pulmonary interstitial fluid accumulation as an aid in the
prevention of overt HAPE.
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